mephenytoin


Also found in: Dictionary, Thesaurus, Wikipedia.
Related to mephenytoin: Mesantoin, methoin

mephenytoin

 [mef″en-ĭ´to-in]
an anticonvulsant administered orally in treatment of several types of epilepsy when the seizures are refractory to other drugs.

mephenytoin

/me·phen·y·to·in/ (mĕ-fen´ĭ-to″in) an anticonvulsant used for the control of a variety of epileptic seizures.

mephenytoin

A drug formerly used to control seizures and convulsions (e.g., from epilepsy); it is no longer available in the US or UK.

mephenytoin

Mesantoin® A drug used to control seizures, convulsions, epilepsy; it is metabolized in liver to pharmacologically active normephenytoin, excreted in urine. See Therapeutic drug monitoring.

mephenytoin

(məfen´ətō´ən),
n brand name: Mesantoin;
drug class: hydantoin anticonvulsant;
action: reduces electrical discharges in motor cortex, reducing seizures;
uses: generalized tonic-clonic seizures, single or complex-partial seizures.

mephenytoin, methoin

a hydantoin anticonvulsant drug, similar to phenytoin, but more toxic.
References in periodicals archive ?
Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese.
Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism.
Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations.
Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype.
Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism.
One recent study on the causes of drug-induced hepatitis revealed a relation between Atrium[R] (a combination preparation of phenobarbital, febarbamate, and difebarbamate)-induced hepatitis and the PM phenotype of mephenytoin hydroxylase X68].
Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents.
Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study.
Hydroxylation polymorphisms of debrisoquin and mephenytoin in European populations.
In vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme.
Possible association between poor metabolism of mephenytoin and hepatotoxicity caused by Atrium, a fixed combination preparation contain ing phenobarbital, febarbamate and difebarbamate.
Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms.